Cost-effectiveness of screening for DPYD polymorphisms to prevent neutropenia in cancer patients treated with fluoropyrimidines

被引：34
作者：
Cortejoso, Lucia [1 ]
Garcia-Gonzalez, Xandra [1 ]
Garcia, Maria I. [1 ]
Garcia-Alfonso, Pilar [2 ]
Sanjurjo, Maria [1 ]
Lopez-Fernandez, Luis A. [1 ]
机构：
[1] Univ Gregorio Maranon, Dept Pharm, Inst Invest Sanitaria Gregorio Maranon, Gen Hosp, Doctor Esquerdo 46, Madrid 28007, Spain
[2] Univ Gregorio Maranon, Med Oncol Dept, Inst Invest Sanitaria Gregorio Maranon, Gen Hosp, Doctor Esquerdo 46, Madrid 28007, Spain
来源：
PHARMACOGENOMICS | 2016年 / 17卷 / 09期
关键词：
5-fluorouracil; capecitabine; drug adverse reactions; METASTATIC COLORECTAL-CANCER; TOXICITY; THERAPY; CAPECITABINE; 5-FLUOROURACIL; METAANALYSIS;
D O I：
10.2217/pgs-2016-0006
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Aim: To compare the cost of screening for three mutations in the dihydropyrimidine dehydrogenase gene and the costs of treating severe fluoropyrimidine-induced neutropenia. Materials & methods: The polymorphisms rs3918290 (DPYD(star)2A), rs67376798 (DPYD 2846A>T) and rs55886062 (1679T>G, DPYD(star)13) were genotyped using real-time PCR, TaqMan probes and a rapid cell lysis to provide PCR-ready DNA. Results: We found that genotyping 1000 patients in our center cost (sic)6400 and that the mean cost of treating severe neutropenia was (sic)3044. Therefore, if severe fluoropyrimidine-induced neutropenia is reduced by genotyping the three DPYD variations in at least 2.21 cases per 1000 treated patients, then DPYD genotyping will prove cost effective. Conclusion: We demonstrated that real-time DPYD genotyping using TaqMan probes is cost effective in all fluoropyrimidine-based treatments.
引用
收藏
页码：979 / 984
页数：6
相关论文
共 15 条
  • [1] Should capecitabine replace 5-fluorouracil in the first-line treatment of metastatic colorectal cancer?
    Aguado, Carlos
    Garcia-Paredes, Beatriz
    Jhonatan Sotelo, Miguel
    Sastre, Javier
    Diaz-Rubio, Eduardo
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (20) : 6092 - 6101
  • [2] Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment
    Amstutz, Ursula
    Farese, Simone
    Aebi, Stefan
    Largiader, Carlo R.
    [J]. PHARMACOGENOMICS, 2009, 10 (06) : 931 - 944
  • [3] XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results
    Cassidy, J.
    Clarke, S.
    Diaz-Rubio, E.
    Scheithauer, W.
    Figer, A.
    Wong, R.
    Koski, S.
    Rittweger, K.
    Gilberg, F.
    Saltz, L.
    [J]. BRITISH JOURNAL OF CANCER, 2011, 105 (01) : 58 - 64
  • [4] Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing
    Caudle, K. E.
    Thorn, C. F.
    Klein, T. E.
    Swen, J. J.
    McLeod, H. L.
    Diasio, R. B.
    Schwab, M.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 94 (06) : 640 - 645
  • [5] Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis
    Deenen, Maarten J.
    Meulendijks, Didier
    Cats, Annemieke
    Sechterberger, Marjolein K.
    Severens, Johan L.
    Boot, Henk
    Smits, Paul H.
    Rosing, Hilde
    Mandigers, Caroline M. P. W.
    Soesan, Marcel
    Beijnen, Jos H.
    Schellens, Jan H. M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (03) : 227 - U77
  • [6] Relationship between Single Nucleotide Polymorphisms and Haplotypes in DPYD and Toxicity and Efficacy of Capecitabine in Advanced Colorectal Cancer
    Deenen, Maarten J.
    Tol, Jolien
    Burylo, Artur M.
    Doodeman, Valerie D.
    de Boer, Anthonius
    Vincent, Andrew
    Guchelaar, Henk-Jan
    Smits, Paul H. M.
    Beijnen, Jos H.
    Punt, Cornelis J. A.
    Schellens, Jan H. M.
    Cats, Annemieke
    [J]. CLINICAL CANCER RESEARCH, 2011, 17 (10) : 3455 - 3468
  • [7] Personalizing Colon Cancer Adjuvant Therapy: Selecting Optimal Treatments for Individual Patients
    Dienstmann, Rodrigo
    Salazar, Ramon
    Tabernero, Josep
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (16) : 1787 - +
  • [8] Garcia-Gonzalez Xandra, 2016, Drug Metabolism and Personalized Therapy, V31, P9, DOI 10.1515/dmpt-2015-0031
  • [9] Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil/capecitabine therapy
    Mercier, Cedric
    Ciccolini, Joseph
    [J]. CLINICAL COLORECTAL CANCER, 2006, 6 (04) : 288 - 296
  • [10] Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data
    Meulendijks, Didier
    Henricks, Linda M.
    Sonke, Gabe S.
    Deenen, Maarten J.
    Froehlich, Tanja K.
    Amstutz, Ursula
    Largiader, Carlo R.
    Jennings, Barbara A.
    Marinaki, Anthony M.
    Sanderson, Jeremy D.
    Kleibl, Zdenek
    Kleiblova, Petra
    Schwab, Matthias
    Zanger, Ulrich M.
    Palles, Claire
    Tomlinson, Ian
    Gross, Eva
    van Kuilenburg, Andre B. P.
    Punt, Cornelis J. A.
    Koopman, Miriam
    Beijnen, Jos H.
    Cats, Annemieke
    Schellens, Jan H. M.
    [J]. LANCET ONCOLOGY, 2015, 16 (16) : 1639 - 1650
12